CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 303 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02964247
NCT02964247Phase 3Completed
CompareCT.gov

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Novo Nordisk A/S·interventional·Posted Nov 16, 2016·Updated Nov 17, 2020

In Brief

A Phase 3 clinical trial evaluating liraglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 303 participants across 82 sites in 7 countries.

Detailed Summary

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesBrazil, India, Israel, Puerto Rico, Russia, United Arab Emirates, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 16, 2016
Enrollment StartMar 3, 2017
Primary CompletionMay 4, 2018
Study CompletionMay 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.6 years ago

Interventions

liraglutidedrug

Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks

placebodrug

Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks